Background: Established traumatic memories have a selective vulnerability to pharmacologic interventions following their reactivation that can decrease subsequent memory recall. This vulnerable period following memory reactivation is termed reconsolidation. The pharmacology of traumatic memory reconsolidation has not been fully characterized despite its potential as a therapeutic target for established, acquired anxiety disorders including posttraumatic stress disorder (PTSD). The mammalian target of rapamycin (mTOR) kinase is a critical regulator of mRNA translation and is known to be involved in various forms of synaptic plasticity and memory consolidation. We have examined the role of mTOR in traumatic memory reconsolidation.
Introduction
Newly formed fear memories undergo a process of consolidation immediately following training which is required for long-term maintenance of the memory trace (Abel & Lattal, 2001; Dudai, 2004; Nader, Schafe, & Le Doux, 2000a) . Protein synthesis inhibitors and other pharmacologic agents interfere with memory consolidation (Bourtchouladze et al., 1998; Davis & Squire, 1984; Flexner, Flexner, De La Haba, & Roberts, 1965; McGaugh, 2000) . Also, growing evidence suggests that fear memories have a selective sensitivity to pharmacologic interventions, including protein synthesis inhibitors, after reactivation, that negatively affect subsequent memory (Nader et al., 2000a; Pedreira & Maldonado, 2003; Przybyslawski & Sara, 1997; Sara, 2000; Schneider & Sherman, 1968; Suzuki et al., 2004; Tronel & Alberini, 2007) . Pharmacologic vulnerability to the protein synthesis inhibitor anisomycin following reactivation empirically defines the ''reconsolidation" phase of memory (Abel & Lattal, 2001; Dudai, 2004; Lattal & Abel, 2004; Nader et al., 2000a) . Established
